Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Ascendis Pharma (ASND – Research Report) today and set a price target of ...

A phase 3 trial of AstraZeneca’s $800 million rare disease candidate has met its primary endpoint. The update keeps ...

Assetmark Inc. raised its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND – Free Report) by 32.9% in the 4th quarter, ...

Ascendis Health's journey from near-bankruptcy to profitability showcases how strategic leadership and financial discipline ...

J.P. Morgan analyst Jessica Fye maintained a Buy rating on Insmed (INSM – Research Report) on March 14 and set a price target of $90.00. The ...

Check Out Our Latest Analysis on Ascendis Pharma A/S Ascendis Pharma A/S Price Performance NASDAQ:ASND opened at $138.18 on Tuesday. The stock has a market cap of $8.39 billion, a P/E ratio of -19 ...

Detailed price information for Ascendis Pharma ADR (ASND-Q) from The Globe and Mail including charting and trades.

Ascendis Pharma A/S (NASDAQ:ASND), a biopharmaceutical company with a $9.07 billion market capitalization focused on developing transformative therapies for rare endocrine disorders, has been ...

Ascendis Pharma A/S (NASDAQ:ASND), a biopharmaceutical company with a $9.07 billion market capitalization focused on developing transformative therapies for rare endocrine disorders, has been ...

Buying $1000 In ASND: If an investor had bought $1000 of ASND stock 15 years ago, it would be worth $55,812.96 today based on a price of $151.93 for ASND at the time of writing.

This page features the latest news about the Ascendis Pharma AS stock. Ascendis Pharma completes enrollment in late-stage study of TransCon Growth Hormone in pediatric growth hormone deficiency ...